Prognostic value of progesterone receptor expression in tubo‐ovarian high‐grade serous carcinoma of the COEUR cohort
暂无分享,去创建一个
[1] C. Le Page,et al. Characteristics and outcome of the COEUR Canadian validation cohort for ovarian cancer biomarkers , 2018, BMC Cancer.
[2] Xueqiong Zhu,et al. Prognostic value of progesterone receptor expression in ovarian cancer: a meta-analysis , 2017, Oncotarget.
[3] M. Köbel,et al. Association of Hormone Receptor Expression with Survival in Ovarian Endometrioid Carcinoma: Biological Validation and Clinical Implications , 2017, International journal of molecular sciences.
[4] M. Köbel,et al. Molecular alterations in indolent, aggressive and recurrent ovarian low‐grade serous carcinoma , 2017, Histopathology.
[5] S. Leung,et al. An Immunohistochemical Algorithm for Ovarian Carcinoma Typing , 2016, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.
[6] R. Labianca,et al. Assessment of a HER2 scoring system for colorectal cancer: results from a validation study , 2015, Modern Pathology.
[7] A. Whittemore,et al. Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study. , 2013, The Lancet. Oncology.
[8] I. Ellis,et al. Investigating AP-2 and YY1 protein expression as a cause of high HER2 gene transcription in breast cancers with discordant HER2 gene amplification , 2009, Breast Cancer Research.
[9] L. Goldstein,et al. High concordance between immunohistochemistry and fluorescence in situ hybridization testing for HER2 status in breast cancer requires a normalized IHC scoring system , 2008, Modern Pathology.
[10] C. Sotiriou,et al. Polysomy 17 in HER-2/neu Status Elaboration in Breast Cancer: Effect on Daily Practice , 2005, Clinical Cancer Research.